(Q40042698)

16 September 2017

Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides (English)

1 reference

transitional cell carcinoma

16 September 2017

1 reference

1

Christian Bolenz

1 reference

16 September 2017

Andreas Becker

2

1 reference

16 September 2017

Lutz Trojan

3

1 reference

16 September 2017

Axel Schaaf

4

1 reference

16 September 2017

Yanwei Cao

5

1 reference

16 September 2017

Christel Weiss

6

1 reference

16 September 2017

Peter Alken

7

1 reference

16 September 2017

Maurice Stephan Michel

8

1 reference

16 September 2017

1 November 2007

1 reference

16 September 2017

1 reference

16 September 2017

25

1 reference

16 September 2017

476-482

1 reference

16 September 2017

6

1 reference

Guidelines on bladder cancer

16 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Antisense oligonucleotide therapy for urologic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

The role of antisense oligonucleotides in the treatment of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Apoptosis and chemotherapy resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Surgical management of bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Programmed cell death and radioresistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Antisense therapy for cancer--the time of truth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.01.017

10.1016/J.UROLONC.2007.01.017

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference